Association between tobacco smoking and bipolar affective disorder: clinical, epidemiological, cross-sectional, retrospective study in outpatients

Kreinin, Anatoly; Novitski, Dmitri; Rabinowitz, D.; Weizman, Abraham; Grinshpoon, Alexander

doi:10.1016/j.comppsych.2011.04.063

Cited by 35 publications

(42 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Obesity was found to be as high as 55% in patients with bipolar disorder, resulting from not only risk health behaviors but also the neurohormone effect of psychotropic agents [15,25,26], which provided an inflammatory and prothrombotic source with multiple organ involvement including cardiovascular disease. Smoking and alcohol/substance use in patients with bipolar disorder was common and was strongly linked to general medical conditions [27,28].…”

Section: Discussionmentioning

confidence: 99%

Increased risk of hyperlipidemia in patients with bipolar disorder: a population-based study

Hsu

Chien

Lin

2015

General Hospital Psychiatry

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Increased risk of hyperlipidemia in patients with bipolar disorder: a population-based study

Hsu

Chien

Lin

2015

General Hospital Psychiatry

View full text Add to dashboard Cite

“…20,21,22 It is not known whether this lower rate of smoking cessation is due to lower effectiveness of smoking cessation treatments in this population or lower availability and/or utilisation of such effective treatments in this population.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta‐analysis

et al. 2016

View full text Add to dashboard Cite

Background and aims To assess the efficacy and tolerability of adjunctive pharmacotherapy for smoking cessation in adults with serious mental illness (SMI) by means of a systematic review and network meta-analysis. Method We searched Embase, Medline, PsychINFO and the Cochrane Central Register of Controlled Trials, from database inception to 1 December 2014 for randomised controlled trials (RCTs) published in English. We included all studies of smokers with SMI (including schizophrenia, schizoaffective disorder, bipolar disorder, delusional disorder and depressive psychoses) who were motivated to quit smoking. Pharmacotherapies included nicotine replacement therapy (NRT), bupropion and varenicline delivered as monotherapy or in combination compared with each other or placebo. The efficacy outcome was self-reported sustained smoking cessation, biochemically verified at the longest reported time point. The tolerability outcome was number of patients discontinuing the trial due to any adverse event Results Seventeen study reports were included which represented fourteen individual RCTs. No trials were found in patients with depressive psychoses, delusional disorder or which compared NRT monotherapy with placebo. A total of 356 and 423 participants were included in the efficacy and tolerability analyses respectively. From the network meta-analysis both bupropion and varenicline were more effective than placebo (OR 4.51 95% Credible Interval (CrI) 1.45 to 14.04 and OR 5.17 95% CrI 1.78 to 15.06 respectively). Data were insensitive to an assessment of varenicline versus bupropion (OR 1.15 95% CrI 0.24 to 5.45). There were no significant differences in tolerability. All outcomes were rated by GRADE criteria as very low quality. Conclusions The limited evidence available to date suggests that bupropion and varenicline are effective and tolerable for smoking cessation in adults with serious mental illnesses.

show abstract

“…3 Smoking prevalence among adults with serious mental illness (SMI) is higher today, at 53%, than it was in the general population in 1964. 4,5 Recent estimates indicate that 64%–79% of those with schizophrenia spectrum disorders smoke tobacco regularly, 5,6 as do 44–71% of those with bipolar disorder, 5–7 and 43% of those with unipolar depression. 8 People with SMI in the US die approximately 25 years earlier than those without mental illness, primarily from diseases directly attributable to tobacco smoking.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Tobacco Use Disorders in Smokers with Serious Mental Illness

Evins

Cather

Laffer

2015

Harvard Review of Psychiatry

View full text Add to dashboard Cite

Addiction to tobacco-derived nicotine remains highly prevalent in the US, with 18% using daily, but 53% of those with serious mental illness smoke regularly. While smokers with serious mental illness have been excluded from most large nicotine dependence treatment studies, a growing evidence base is emerging to guide clinicians in how to assist their patients with psychiatric illness to quit smoking. The aim of this review is to present the evidence on safety and efficacy of smoking cessation interventions for those with serious mental illness. Smokers with schizophrenia spectrum disorders should receive varenicline or bupropion with or without nicotine replacement therapy (NRT) in combination with behavioral treatment. Preliminary evidence suggests that varenicline in combination with behavioral support is efficacious and well tolerated for smoking cessation for those with bipolar disorder and major depressive disorder. More work is needed to establish treatment guidelines for smokers with major depressive disorder and bipolar disorder. Controlled trials to date have not found evidence for worsening of psychiatric symptoms or increased rate of psychiatric adverse events in this population with available pharmacotherapeutic cessation aids. Converging evidence indicates that a majority of smokers with serious mental illness want to quit smoking and that available pharmacotherapeutic cessation aids combined with behavioral support are both effective for and well tolerated by these smokers. Most people with serious mental illness see their psychiatrist more regularly than their primary care physician, and many receive care exclusively in a psychiatric treatment setting. Psychiatrists thus have an important role to play in the recognition and treatment of tobacco use disorders in people with serious mental illness.

show abstract

Association between tobacco smoking and bipolar affective disorder: clinical, epidemiological, cross-sectional, retrospective study in outpatients

Cited by 35 publications

References 21 publications

Increased risk of hyperlipidemia in patients with bipolar disorder: a population-based study

Increased risk of hyperlipidemia in patients with bipolar disorder: a population-based study

Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta‐analysis

Treatment of Tobacco Use Disorders in Smokers with Serious Mental Illness

Contact Info

Product

Resources

About